These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 21904597)
1. Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation. Mortier A; Berghmans N; Ronsse I; Grauwen K; Stegen S; Van Damme J; Proost P PLoS One; 2011; 6(8):e23913. PubMed ID: 21904597 [TBL] [Abstract][Full Text] [Related]
2. Truncation of CXCL8 to CXCL8(9-77) enhances actin polymerization and in vivo migration of neutrophils. Metzemaekers M; Vandendriessche S; Berghmans N; Gouwy M; Proost P J Leukoc Biol; 2020 Jun; 107(6):1167-1173. PubMed ID: 32272490 [TBL] [Abstract][Full Text] [Related]
3. Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties. Vacchini A; Mortier A; Proost P; Locati M; Metzemaekers M; Borroni EM Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486423 [TBL] [Abstract][Full Text] [Related]
4. A Requirement for Neutrophil Glycosaminoglycans in Chemokine:Receptor Interactions Is Revealed by the Streptococcal Protease SpyCEP. Goldblatt J; Lawrenson RA; Muir L; Dattani S; Hoffland A; Tsuchiya T; Kanegasaki S; Sriskandan S; Pease JE J Immunol; 2019 Jun; 202(11):3246-3255. PubMed ID: 31010851 [TBL] [Abstract][Full Text] [Related]
5. Probing the role of CXC motif in chemokine CXCL8 for high affinity binding and activation of CXCR1 and CXCR2 receptors. Joseph PR; Sarmiento JM; Mishra AK; Das ST; Garofalo RP; Navarro J; Rajarathnam K J Biol Chem; 2010 Sep; 285(38):29262-9. PubMed ID: 20630874 [TBL] [Abstract][Full Text] [Related]
6. CXCL8((3-73))K11R/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8/IL-8. Li F; Zhang X; Gordon JR Biochem Biophys Res Commun; 2002 May; 293(3):939-44. PubMed ID: 12051749 [TBL] [Abstract][Full Text] [Related]
7. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. Nasser MW; Raghuwanshi SK; Grant DJ; Jala VR; Rajarathnam K; Richardson RM J Immunol; 2009 Sep; 183(5):3425-32. PubMed ID: 19667085 [TBL] [Abstract][Full Text] [Related]
8. Heparin-bound chemokine CXCL8 monomer and dimer are impaired for CXCR1 and CXCR2 activation: implications for gradients and neutrophil trafficking. Joseph PRB; Sawant KV; Rajarathnam K Open Biol; 2017 Nov; 7(11):. PubMed ID: 29118271 [TBL] [Abstract][Full Text] [Related]
9. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6. Catusse J; Struyf S; Wuyts A; Weyler M; Loos T; Gijsbers K; Gouwy M; Proost P; Van Damme J Biochem Pharmacol; 2004 Nov; 68(10):1947-55. PubMed ID: 15476666 [TBL] [Abstract][Full Text] [Related]
10. Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8((3-74))K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology. Zhao X; Li F; Town JR; Zhang X; Wang W; Gordon JR Int Immunopharmacol; 2007 Dec; 7(13):1723-31. PubMed ID: 17996682 [TBL] [Abstract][Full Text] [Related]
11. The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. Raghuwanshi SK; Su Y; Singh V; Haynes K; Richmond A; Richardson RM J Immunol; 2012 Sep; 189(6):2824-32. PubMed ID: 22869904 [TBL] [Abstract][Full Text] [Related]
13. Monomeric and dimeric CXCL8 are both essential for in vivo neutrophil recruitment. Das ST; Rajagopalan L; Guerrero-Plata A; Sai J; Richmond A; Garofalo RP; Rajarathnam K PLoS One; 2010 Jul; 5(7):e11754. PubMed ID: 20668677 [TBL] [Abstract][Full Text] [Related]
14. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Russo RC; Garcia CC; Teixeira MM; Amaral FA Expert Rev Clin Immunol; 2014 May; 10(5):593-619. PubMed ID: 24678812 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166 [TBL] [Abstract][Full Text] [Related]
16. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Gabellini C; Trisciuoglio D; Desideri M; Candiloro A; Ragazzoni Y; Orlandi A; Zupi G; Del Bufalo D Eur J Cancer; 2009 Sep; 45(14):2618-27. PubMed ID: 19683430 [TBL] [Abstract][Full Text] [Related]
17. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation. Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598 [TBL] [Abstract][Full Text] [Related]
18. Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity. Mortier A; Loos T; Gouwy M; Ronsse I; Van Damme J; Proost P J Biol Chem; 2010 Sep; 285(39):29750-9. PubMed ID: 20630876 [TBL] [Abstract][Full Text] [Related]
19. NH2- and COOH-terminal truncations of murine granulocyte chemotactic protein-2 augment the in vitro and in vivo neutrophil chemotactic potency. Wuyts A; D'Haese A; Cremers V; Menten P; Lenaerts JP; De Loof A; Heremans H; Proost P; Van Damme J J Immunol; 1999 Dec; 163(11):6155-63. PubMed ID: 10570306 [TBL] [Abstract][Full Text] [Related]
20. Porcine CXCR1/2 antagonist CXCL8 Wang X; Li Y; Li L; Jiao Z; Liu X; Cheng G; Gu C; Hu X; Zhang W Sci Rep; 2020 Jan; 10(1):1210. PubMed ID: 31988368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]